CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Revenues:
License and milestone fees	$ 5,152	$ 26,915	$ 57,815	$ 39,455
Royalty Revenue		195	13,867	10,346
Non-cash royalty revenue related to the sale of future royalties	12,894	25,299	5,484
Research and development support	2,781	4,014	2,848	7,187
Clinical materials revenue	679	3,579	5,527	2,908
Total revenues	21,506	60,002	85,541	59,896
Operating Expenses:
Research and development	66,566	148,077	111,768	106,958
General and administrative	17,995	36,916	28,228	24,469
Restructuring charges	4,431
Total operating expenses	88,992	184,993	139,996	131,427
Loss from operations	(67,486)	(124,991)	(54,455)	(71,531)
Investment income, net	259	325	69	44
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(8,665)	(20,130)	(5,437)
Interest expense on convertible senior notes	(2,249)	(138)
Other (expense) income, net	(742)	117	(916)	123
Net loss	$ (78,883)	$ (144,817)	$ (60,739)	$ (71,364)
Basic and diluted net loss per common share (in dollar per share)	$ (0.91)	$ (1.67)	$ (0.71)	$ (0.83)
Basic and diluted weighted average common shares outstanding (in shares)	87,102	86,976	86,038	85,481
Total comprehensive (loss) income	$ (78,883)	$ (144,817)	$ (60,739)	$ (71,364)